BRD1652
(BRD 1652) manufacturers
- BRD1652
-
- $1520.00
-
2026-07-27
- CAS:1597438-92-0
- Purity:
- Supply Ability: 10g
|
| | BRD1652
(BRD 1652) Basic information |
| Product Name: | BRD1652
(BRD 1652) | | Synonyms: | BRD1652
(BRD 1652);BRD1652;5H-Pyrazolo[3,4-b]quinolin-5-one, 1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-3-(trifluoromethyl)-, (4S)-;(4S)-4,7,7-trimethyl-4-phenyl-3-(trifluoromethyl)-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one | | CAS: | 1597438-92-0 | | MF: | C20H20F3N3O | | MW: | 375.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1597438-92-0.mol |  |
| | BRD1652
(BRD 1652) Chemical Properties |
| | BRD1652
(BRD 1652) Usage And Synthesis |
| Description | BRD1652 is a highly selective and potent GSK3 inhibitor. BRD1652 demonstrates in vivo efficacy in a dopaminergic signaling paradigm modeling mood-related disorders. The mood stabilizer lithium, the first-line treatment for bipolar disorder, is hypothesized to exert its effects through direct inhibition of glycogen synthase kinase 3 (GSK3). | | Uses | BRD1652 is a highly selective GSK3 inhibitor. BRD1652 can be used in the study of emotion-related diseases[1]. | | in vivo | BRD1652 (30 mg/kg intraperitoneal injection, single dose) can reduce amphetamine-induced hyperactivity disorder (AIH) in mice[1].
| | References | [1] Wagner FF, et al. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. 2016 Jul 15;11(7):1952-63. DOI:10.1021/acschembio.6b00306 |
| | BRD1652
(BRD 1652) Preparation Products And Raw materials |
|
|
Tag:BRD1652
(BRD 1652)(1597438-92-0)
Related Product Information
|
|
5H-Pyrazolo[3,4-b]quinolin-5-one, 1,4,6,7,8,9-hexahydro-3,7,7-trimethyl-4-(2-pyridinyl)-
5H-Pyrazolo[3,4-b]quinolin-5-one, 1,4,6,7,8,9-hexahydro-3,7,7-trimethyl-4-(4-pyridinyl)-
3,7,7-Trimethyl-4-(4-pyridinyl)-2,4,6,7,8,9-hexahydro-5H-pyrazolo[3,4-b]quinolin-5-one
3,7,7-Trimethyl-4-phenyl-1,4,6,7,8,9-hexahydro-5H-pyrazolo[3,4-b]quinolin-5-one
4-(1,3-Benzodioxol-5-yl)-3,7,7-trimethyl-2,4,6,7,8,9-hexahydro-5H-pyrazolo[3,4-b]quinolin-5-one
BRD0705
|